Penclomedine

Penclomedine

SCHEMBL188460

COc1nc(C(Cl)(Cl)Cl)c(Cl)c(OC)c1Cl

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Penclomedine SCHEMBL29431894 1.00 CYP1A2 (0.35) CYP1A2
SCHEMBL10013346 0.81 ABCB11 (0.35)
SCHEMBL19841177 0.80
SCHEMBL2905410 0.80 CYP1A2 (0.35) CYP1A2
SCHEMBL7108425 0.78 CYP1A2 (0.48) CYP1A2
SCHEMBL13751437 0.76 CUL4A (0.38)
SCHEMBL13272289 0.69 ABCB11 (0.30)
SCHEMBL7944351 0.68 CYP1A2 (0.35) CYP1A2
SCHEMBL31277708 0.64 KDM4E (0.35)
SCHEMBL13880635 0.64 KDM4E (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4640714-A2 METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST PML Screening, LLC (US) 2025-10-29 EP claimed
US-20250275946-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2025-09-04 US claimed
EP-4177356-B1 METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST PML SCREENING LLC (US) 2024-05-08 EP claimed
US-20240082157-A1 PREPARATION OF LIPOPHILIC ACTIVE INGREDIENTS SPI PHARMA, INC. (US) 2024-03-14 US claimed
EP-4177356-A1 METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST PML Screening, LLC (US) 2023-05-10 EP claimed
US-11534375-B2 Solvent-free method of encapsulating a hydrophobic active AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-12-27 US claimed
EP-3625368-B1 METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING PML SCREENING LLC (US) 2022-11-09 EP claimed
WO-2022169634-A9 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-09-22 WO claimed
US-20220257772-A1 PREPARATION OF LIPOPHILIC ACTIVE INGREDIENTS SPI PHARMA, INC. (US) 2022-08-18 US claimed
WO-2022169634-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-08-11 WO claimed
US-6207178-B1 STABLE SUSPENSION KABI PHARMACIA AB (SE) 2001-03-27 US claimed
US-5785976-A Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof PHARMACIA & UPJOHN AB (SE) 1998-07-28 US claimed
EP-0711151-A1 PARTICLES WITH MODIFIED PHYSICOCHEMICAL PROPERTIES, THEIR PREPARATION AND USES KNOLL AKTIENGESELLSCHAFT (DE) 1996-05-15 EP claimed
EP-0687172-A1 SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF Pharmacia & Upjohn Aktiebolag (SE) 1995-12-20 EP claimed
WO-1995005164-A1 PARTICLES WITH MODIFIED PHYSICOCHEMICAL PROPERTIES, THEIR PREPARATION AND USES WESTESEN KIRSTEN (DE) 1995-02-23 WO claimed
WO-1994020072-A1 SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF PHARMACIA AB (SE) 1994-09-15 WO claimed
EP-0260524-B1 3,5-Dichloro-2,4-dimethoxy-6-(trichloromethyl) pyridine DOW CHEMICAL CO (US) 1994-01-05 EP claimed
WO-1992017162-A1 LYOPHILIZED EMULSION WARNER-LAMBERT COMPANY (US) 1992-10-15 WO claimed
EP-0260524-A2 3,5-Dichloro-2,4-dimethoxy-6-(trichloromethyl) pyridine THE DOW CHEMICAL COMPANY (US) 1988-03-23 EP claimed
US-4717726-A LEUKEMIA, LYMPHOMA, BREAST AND OVARIAN CANCER THE DOW CHEMICAL COMPANY (US) 1988-01-05 US claimed